Prescribing Information
Important Safety Information
Patient Site
Contact Us

Patient Support and Resources

The Navigator ProgramTM helps your patients 
start and stay on CUVRIOR

Ready to enroll your patients?
Use the CUVRIOR Start Form
Download

Orphalan is committed to helping patients access CUVRIOR

  • The Navigator ProgramTM is a no-cost program created to provide access support to your patients throughout their entire CUVRIOR treatment journey
  • Once enrolled, patients will work with a dedicated Care Coordinator who will help them navigate the process, and provide education and access support
Learn more about the Navigator ProgramTM and explore related resources

Quick Start Program

No-cost medication can be made available to eligible patients for a limited time.
View Form

Co-pay Program

Patients with commercial insurance may pay as little as $0/month for CUVRIOR.
Terms and Conditions apply.

Patient Assistance Program 

This program helps patients who may be uninsured or have financial concerns. Enrollment and financial assessment required. 
For questions regarding the Navigator ProgramTM, please call a Care Coordinator at 1-877-995-ORPH (6774).

Explore HCP quick links

Sign up to receive email updates. 
Use the CUVRIOR Dosing Calculator.
Enroll patients in the Navigator ProgramTM with the CUVRIOR Start Form.
See a sample Letter of Medical Necessity.
Download the Navigator 
Reimbursement Guide.
Review and download a statutory price disclosure form for CO, CT, or VT.

Your patients might find these resources helpful

Prescribing Information
Wilson Disease Association
CUVRIOR Patient Education Brochure
Wilson Disease Association Nutrition Guidance

Ready to enroll your patients 
in the Navigator ProgramTM?

Download the CUVRIOR Start Form to get the 
process started.

Indication & Important Safety Information

CUVRIOR is a copper chelator indicated for the treatment of adult patients with stable Wilson Disease who are de-coppered and tolerant to penicillamine. Please see full Prescribing Information.
Important Safety Information

INDICATION

CUVRIOR is a copper chelator indicated for the treatment of adult patients with stable Wilson disease who are de-coppered and tolerant to penicillamine.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

  • CUVRIOR is contraindicated in patients with hypersensitivity to trientine or to any of the excipients in CUVRIOR.

WARNINGS AND PRECAUTIONS

  • Potential for Worsening of Clinical Symptoms at Initiation of Therapy, including neurological deterioration, may occur at the beginning of CUVRIOR therapy due to mobilization of excess stores of copper. Adjust the dosage or discontinue therapy if clinical condition worsens. Evaluate serum non-ceruloplasmin copper (NCC) levels or 24-hour urinary copper excretion (UCE) when initiating treatment, after 3 months, and approximately every 6 months thereafter.
  • Copper Deficiency may develop following treatment with CUVRIOR. Periodic monitoring is required.
  • Iron Deficiency may develop following treatment with CUVRIOR. If iron deficiency develops, a short course of iron supplementation may be given.
  • Hypersensitivity Reactions, characterized by rash, have been reported with the use of trientine. Rash was reported in 12% (3/26) of CUVRIOR-treated patients, and one patient discontinued treatment due to rash. If rash or other hypersensitivity reaction occurs, consider discontinuing CUVRIOR.

ADVERSE REACTIONS

The most common adverse reactions (>5%) are abdominal pain, change of bowel habits, rash, alopecia, and mood swings.

DRUG INTERACTIONS

  • Mineral Supplements (e.g. iron, zinc, calcium, magnesium): Avoid concomitant use. If concomitant use is unavoidable, take CUVRIOR at least 2 hours before or 2 hours after iron and take CUVRIOR at least 1 hour before or 2 hours after other mineral supplements.
  • Other Drugs for Oral Administration: Take CUVRIOR at least 1 hour apart from any other oral drug.

To report SUSPECTED ADVERSE REACTIONS, contact Orphalan at 1-800-961-8320 or FDA at 1-800-FDA-1088 or 
www.fda.gov/medwatch.

Please see full Prescribing Information.